CN103874510A - Pacap作为用于疫苗的分子佐剂的用途 - Google Patents

Pacap作为用于疫苗的分子佐剂的用途 Download PDF

Info

Publication number
CN103874510A
CN103874510A CN201280041829.5A CN201280041829A CN103874510A CN 103874510 A CN103874510 A CN 103874510A CN 201280041829 A CN201280041829 A CN 201280041829A CN 103874510 A CN103874510 A CN 103874510A
Authority
CN
China
Prior art keywords
pacap
fish
group
peptide
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280041829.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·卢戈冈萨雷斯
Y·卡皮奥冈萨雷斯
M·P·埃斯特拉达加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of CN103874510A publication Critical patent/CN103874510A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280041829.5A 2011-08-26 2012-08-24 Pacap作为用于疫苗的分子佐剂的用途 Pending CN103874510A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2011-0167 2011-08-26
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas

Publications (1)

Publication Number Publication Date
CN103874510A true CN103874510A (zh) 2014-06-18

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280041829.5A Pending CN103874510A (zh) 2011-08-26 2012-08-24 Pacap作为用于疫苗的分子佐剂的用途

Country Status (20)

Country Link
US (1) US9549977B2 (https=)
EP (1) EP2749291B1 (https=)
JP (1) JP6077541B2 (https=)
KR (1) KR101857705B1 (https=)
CN (1) CN103874510A (https=)
AU (1) AU2012303887B2 (https=)
BR (1) BR112014004620B1 (https=)
CA (1) CA2844898C (https=)
CL (1) CL2014000386A1 (https=)
CU (1) CU24075B1 (https=)
ES (1) ES2648337T3 (https=)
MX (1) MX351725B (https=)
MY (1) MY191697A (https=)
NO (1) NO2749291T3 (https=)
PH (1) PH12014500397B1 (https=)
PT (1) PT2749291T (https=)
RU (1) RU2580294C2 (https=)
SG (1) SG11201400215SA (https=)
WO (1) WO2013029570A1 (https=)
ZA (1) ZA201401271B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117617183A (zh) * 2023-11-29 2024-03-01 中国医学科学院医药生物技术研究所 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
US20220202905A1 (en) * 2019-05-14 2022-06-30 Senju Pharmaceutical Co., Ltd. Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064378A2 (en) * 2004-12-13 2006-06-22 Maria Teresa De Magistris Adjuvant activity of gastrointestinal peptides
EP1956031A1 (en) * 2005-11-22 2008-08-13 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Neuropeptides for the culture of aquatic organisms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
CA2379604A1 (en) * 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
CA2779496A1 (en) * 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064378A2 (en) * 2004-12-13 2006-06-22 Maria Teresa De Magistris Adjuvant activity of gastrointestinal peptides
EP1956031A1 (en) * 2005-11-22 2008-08-13 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Neuropeptides for the culture of aquatic organisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEI MU XIN ET AL.: "A study of structure-activity relationship of PACAP", 《CHINA NATL J NEW GASTROENTEROL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117617183A (zh) * 2023-11-29 2024-03-01 中国医学科学院医药生物技术研究所 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用

Also Published As

Publication number Publication date
ZA201401271B (en) 2015-04-29
CA2844898A1 (en) 2013-03-07
WO2013029570A1 (es) 2013-03-07
CA2844898C (en) 2021-06-22
ES2648337T3 (es) 2018-01-02
JP6077541B2 (ja) 2017-02-08
MY191697A (en) 2022-07-07
AU2012303887B2 (en) 2017-06-22
MX351725B (es) 2017-10-25
KR101857705B1 (ko) 2018-06-20
CU20110167A7 (es) 2013-06-28
PH12014500397A1 (en) 2014-04-14
MX2014002214A (es) 2014-04-30
US20140294889A1 (en) 2014-10-02
US9549977B2 (en) 2017-01-24
KR20140064847A (ko) 2014-05-28
EP2749291A1 (en) 2014-07-02
CU24075B1 (es) 2015-01-29
BR112014004620B1 (pt) 2019-10-29
CL2014000386A1 (es) 2014-07-11
EP2749291B1 (en) 2017-10-18
PH12014500397B1 (en) 2018-09-12
PT2749291T (pt) 2017-11-24
RU2014111465A (ru) 2015-10-10
RU2580294C2 (ru) 2016-04-10
JP2014524450A (ja) 2014-09-22
BR112014004620A2 (pt) 2017-03-21
NO2749291T3 (https=) 2018-03-17
SG11201400215SA (en) 2014-09-26
AU2012303887A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
Chang et al. Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model
CN104884084B (zh) 鱼用亚单位浸泡疫苗
JP2002516294A (ja) 粘膜免疫を誘導するための方法および産物
CN117050986B (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
Thwaite et al. Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole
Caipang et al. Profiling gene expression in the spleen of Atlantic cod, Gadus morhua upon vaccination with Vibrio anguillarum antigen
Hynes et al. Immune response of Atlantic salmon to recombinant flagellin
JP6077541B2 (ja) ワクチンのための分子アジュバントとしてのｐａｃａｐの使用
Gorgoglione et al. Viral and bacterial septicaemic infections modulate the expression of PACAP splicing variants and VIP/PACAP receptors in brown trout immune organs
EP2950816B1 (en) The use of dna sequences encoding an interferon as vaccine adjuvants
Sepúlveda et al. Time-course study of the protection induced by an interferon-inducible DNA vaccine against viral haemorrhagic septicaemia in rainbow trout
Martinez-Alonso et al. Immune responses elicited in rainbow trout through the administration of infectious pancreatic necrosis virus-like particles
EP4382533A1 (en) Protein nanopellets for fish or teleost and crustacean vaccination
KR102062624B1 (ko) 약독화된 살모넬라 갈리나룸 변이주를 유효성분으로 포함하는 조류 인플루엔자 및 가금티푸스 동시 예방 또는 치료용 백신 조성물
CN103298452B (zh) Pacap用于在水生生物中治疗病毒感染的用途
JP5971625B2 (ja) アジュバント、及び水産用ワクチン
EP3328423B1 (en) Enhanced immune response in fish
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
Talebi et al. Efficacy of CpG-ODN administration routes on humoral responses against Newcastle disease in broilers
Dar et al. Immunotherapeutic potential of CpG oligonucleotides in chickens
Carrera et al. Evaluating the adjuvant potential of NK-lysin and HMGB1-derived peptides in enhancing immune responses in Salmo salar
Kaviarasu et al. Bacterial DNA pre-stimulation elevates antiviral gene expression in koi against koi ranavirus (KIRV) infection
Sánchez OPTIMIZING ORAL VACCINES FOR USE IN AQUACULTURE. Bacillus subtilis SPORES AS ADJUVANTS AND ANTIGEN CARRIERS
SIVASANKAR HOST IMMUNE RESPONSES TO RANAVIRUS INFECTION IN MARINE AND FRESHWATER FISHES
TW202203970A (zh) 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140618

RJ01 Rejection of invention patent application after publication